Darnitsa continues producing new medicinal products during the war24 May 2022
Darnitsa constantly monitors the needs of the patients, the latest medical research and market opportunities to help healthcare professionals and patients improve their quality of life through science, innovation and accessibility.
The cycle of new drug development starts with the study of the needs of our market, prevalence of diseases among the population and the competitive environment. Also we refer to the latest leading international guidelines and guides within this process. For example, currently the most burning health issues for Ukrainians are nervous system disorders, pain of different genesis and, above all, diseases of the cardiovascular system. Therefore, Darnitsa Company has chosen to address these issues as its strategic areas of its activities.
The war only confirmed the relevance of these areas. In March, the most increased sales on the market (and in Darnitsa sales) included the medicinal products that act on the cardiovascular system (+23% on the market, +45% in Darnitsa sales) and nervous system, primarily analgesics (+51% on the market, +37% in Darnitsa sales) and psycholeptics (+56% on the market, +46% in Darnitsa sales).*
In May, two new drugs from Darnitsa appeared on the shelves of the pharmacies.
PERINDOPRES® TRIO** is a modern triple antihypertensive combination (perindopril, indapamid and amlodipine), i.e. it is a potent and reliable tool to manage the blood pressure. When we talk about the cardiac patients who are indicated the daily intake of many tablets, the simple “convenience of administration” turns into “quality of life”.
What are the advantages of Perindopress Trio?
- One of the triple combinations mostly trusted by doctors and patients
- Bioequivalence proven in the competent international laboratory approved by FDA and EU
- Affordable price
- Supplements the Perindopresses line allowing personalization of antihypertensive therapy for each patient
And the most important aspect: supporting the Ukrainian producer today is the reconstruction of the state tomorrow.
Also, the range of Darnitsa analgesics was expanded with medicinal product DEXPRO®*** granules in sachets. This medicinal product will be a wonderful supplement to the injectable product Dexpro which long ago has achieved a stable position among parenteral analgesics in the pharmaceutical market of Ukraine.
Dexpro granules contain active substance dexketoprofen trometamol and belong to the class of non-steroidal anti-inflammatory drugs (NSAIDs).
Dexpro granules are used for pain relief in different situations: traumas, musculoskeletal pain, dysmenorrhea, toothache and more.
Advantages of Dexpro granules:
- Marked analgesic effect
- Analgesic effect is achieved 30 minutes after administration
- Easy-to-use product: dissolve the entire content of one sachet in a glass of water and drink.
“Even during the war, Darnitsa looks to the future. We have not stopped the manufacture even for a day, and we continue producing the new drugs. Two new drugs will appear on pharmacy shelves in May. Earlier we reported that we received a license to develop and manufacture a generic version of the oral anticoagulant Paxlovid from Pfizer. We are also recognized by the WHO as the only company in Ukraine to receive mRNA technology for vaccines, which allows us selling these medicinal products to 95 countries and significantly expands our export horizons. Therefore, the Ukrainian pharmaceutical business stands on the pharmaceutical guard of the country!” — told Andriy Obrizan, general director of pharmaceutical company Darnitsa.
PJSC Pharmaceutical Company Darnitsa was established in 1930. Since 1998, Darnitsa has been a Ukrainian leader by the volume of drug production on the basis of quantities. Strategic areas of portfolio development are cardiology, neurology and pain management. During the war, 1.3 million packages of medicinal products on the amount of UAH 108.5 million were donated to the Ministry of Health, the Armed Forces of Ukraine, hospitals and charitable organizations.
*According to Proxima Research
** Perindopress Trio, Marketing Authorizations No. UA/19239/01/04, UA/19239/01/03, UA/19239/01/02, UA/19239/01/01
*** Dexpro, Marketing Authorization No. UA/17373/02/01
The information is intended exclusively for distribution in specialized publications intended for medical institutions and doctors